Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Int...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Walsh GM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/9f1517d6c94a4b8e9e05febf8080da4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9f1517d6c94a4b8e9e05febf8080da4a
record_format	dspace
spelling	oai:doaj.org-article:9f1517d6c94a4b8e9e05febf8080da4a2021-12-02T05:09:40ZProfile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma1177-54751177-5491https://doaj.org/article/9f1517d6c94a4b8e9e05febf8080da4a2013-01-01T00:00:00Zhttp://www.dovepress.com/profile-of-reslizumab-in-eosinophilic-disease-and-its-potential-in-the-a11900https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil&trade;) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.Keywords: IL-5, asthma, eosinophilWalsh GMDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 7-11 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Walsh GM Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
description	Garry M WalshDivision of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UKAbstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil&trade;) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.Keywords: IL-5, asthma, eosinophil
format	article
author	Walsh GM
author_facet	Walsh GM
author_sort	Walsh GM
title	Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
title_short	Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
title_full	Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
title_fullStr	Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
title_full_unstemmed	Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
title_sort	profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/9f1517d6c94a4b8e9e05febf8080da4a
work_keys_str_mv	AT walshgm profileofreslizumabineosinophilicdiseaseanditspotentialinthetreatmentofpoorlycontrolledeosinophilicasthma
_version_	1718400548462395392

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Ejemplares similares